Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

MBCProject_0044_T1_RNA

· A

d1d0cb1d-1421-5bd6-94bc-70b34f4f39ac

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
cancer_type_detailed
subtype
A
subtype
A

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.470
  • HEDGEHOG_SIGNALING+0.370
  • UV_RESPONSE_DN+0.370
  • WNT_BETA_CATENIN_SIGNALING+0.330
  • ANGIOGENESIS+0.310
  • TGF_BETA_SIGNALING+0.290
  • MITOTIC_SPINDLE+0.280
  • APICAL_JUNCTION+0.220
  • MYOGENESIS+0.170
  • NOTCH_SIGNALING+0.150

Top 10 suppressed

  • MYC_TARGETS_V1-0.420
  • MTORC1_SIGNALING-0.410
  • OXIDATIVE_PHOSPHORYLATION-0.410
  • REACTIVE_OXYGEN_SPECIES_PATHWAY-0.390
  • ALLOGRAFT_REJECTION-0.360
  • INTERFERON_ALPHA_RESPONSE-0.360
  • INTERFERON_GAMMA_RESPONSE-0.340
  • MYC_TARGETS_V2-0.300
  • IL6_JAK_STAT3_SIGNALING-0.290
  • ADIPOGENESIS-0.260

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-D8-A1XB-01A-11R-A14D-07
breast-umap@18
A0.874
2ERR2208936
melanoma-umap@29
0.865
3SRR6013521
lung-landscapes@6
cohortA10.849
4X8de42096.ef3e.4864.8ee1.2ee7672c1c82
lung-landscapes@6
cohortSQ10.848
57900174d-af00-444f-a5b2-226a45f7e76a
colon-landscapes@1
0.840
6SRR8613779
breast-umap@18
D0.838
7f825534d-5882-4efe-a32e-af56741854f6
colon-landscapes@1
0.833
820140156.TNBC
breast-umap@18
D0.829
9TCGA-56-8626-01A-11R-2403-07
lung-landscapes@6
cohortSQ10.818
10SRR8613798
breast-umap@18
D0.818

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 15 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
EPITHELIAL_MESENCHYMAL_TRANSITION0.470Inavolisib— uncovered
HEDGEHOG_SIGNALING0.370Inavolisib— uncovered
UV_RESPONSE_DN0.370Inavolisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.330Inavolisib— uncovered
ANGIOGENESIS0.310Remibrutinib— uncovered
TGF_BETA_SIGNALING0.290Inavolisib— uncovered
MITOTIC_SPINDLE0.280Inavolisib— uncovered
APICAL_JUNCTION0.220Inavolisib— uncovered
MYOGENESIS0.170Inavolisib— uncovered
NOTCH_SIGNALING0.150Inavolisib— uncovered
APICAL_SURFACE0.130Temsirolimus— uncovered
PANCREAS_BETA_CELLS0.060Cobimetinib— uncovered
TNFA_SIGNALING_VIA_NFKB0.060Inavolisib— uncovered
ESTROGEN_RESPONSE_EARLY0.030Inavolisib— uncovered
KRAS_SIGNALING_UP0.030Inavolisib— uncovered